Fig. 5

Prediction of immunotherapy efficacy using TSCMS in the IMvigor210 cohort. A Box plot of PD1 expression in high-risk and low-risk groups. B Box plot of PD-L1 expression in high-risk and low-risk groups. C Box plot of TSCMS scores in the anti-PD-L1 treatment group. D Box plot of CTLA4 expression in high-risk and low-risk groups. E Bar chart showing treatment response proportions in high-risk and low-risk groups. F Kaplan–Meier plot of TSCMS in the IMvigor210 Cohort